Efficacy you and your patients can see


Some patients see noticeable improvements to the arms, back, hips and/or legs
as early as week 14


More than a foam spray, superior efficacy1,5

More than half of Enstilar® patients achieved treatment success* at week 41,5


*Treatment success is defined as clear or almost clear from baseline moderate to severe disease or clear from baseline mild disease. Requiring at least a 2-step improvement in PGA.


Innovative foam spray application

Watch Winnie Woo, our Senior Medical Science Liasion explain how the foam spray impacts the efficacy of Enstilar®.

Similar tolerability with superior efficacy to Daivobet®1

Study versus Daivobet® ointment:

The frequency of adverse events, most of which were mild, was low and comparable between the two active treatment groups1
The most frequently reported adverse reactions during treatment are application site reactions including pain; pruritis and irritation2



“Even with the greater efficacy reported…this is not accompanied with any compromise in safety“1